Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase.


Journal

Bioorganic & medicinal chemistry letters
ISSN: 1464-3405
Titre abrégé: Bioorg Med Chem Lett
Pays: England
ID NLM: 9107377

Informations de publication

Date de publication:
01 05 2021
Historique:
received: 17 11 2020
revised: 10 02 2021
accepted: 21 02 2021
pubmed: 9 3 2021
medline: 2 9 2021
entrez: 8 3 2021
Statut: ppublish

Résumé

Free Energy Perturbation (FEP) calculations can provide high-confidence predictions of the interaction strength between a ligand and its protein target. We sought to explore a series of triazolopyrimidines which bind to the EED subunit of the PRC2 complex as potential anticancer therapeutics, using FEP calculations to inform compound design. Combining FEP predictions with a late-stage functionalisation (LSF) inspired synthetic approach allowed us to rapidly evaluate structural modifications in a previously unexplored region of the EED binding site. This approach generated a series of novel triazolopyrimidine EED ligands with improved physicochemical properties and which inhibit PRC2 methyltransferase activity in a cancer-relevant G401 cell line.

Identifiants

pubmed: 33684441
pii: S0960-894X(21)00130-X
doi: 10.1016/j.bmcl.2021.127904
pii:
doi:

Substances chimiques

Enzyme Inhibitors 0
Ligands 0
Purines 0
triazolopyrimidinone 273-40-5
Polycomb Repressive Complex 2 EC 2.1.1.43

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

127904

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Auteurs

Daniel H O' Donovan (DH)

Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom. Electronic address: daniel.odonovan@astrazeneca.com.

Clare Gregson (C)

Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.

Martin J Packer (MJ)

Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.

Ryan Greenwood (R)

Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.

Kurt G Pike (KG)

Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.

Sameer Kawatkar (S)

Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, United States.

Andrew Bloecher (A)

Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, United States.

James Robinson (J)

Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.

Jon Read (J)

Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.

Erin Code (E)

Discovery Sciences R&D, 35 Gatehouse Drive, Waltham, MA 02451, United States.

Jessie Hao-Ru Hsu (JH)

Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, United States.

Minhui Shen (M)

Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, United States.

Haley Woods (H)

Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, United States.

Peter Barton (P)

Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.

Shaun Fillery (S)

Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.

Beth Williamson (B)

Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.

Philip B Rawlins (PB)

Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.

Sharan K Bagal (SK)

Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH